US 12,129,218 B2
AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same
Yong Tae Kwon, Seoul (KR); Chang Hoon Ji, Seoul (KR); Srinivasrao Ganipisetti, Seoul (KR); Hee Yeon Kim, Seoul (KR); Su Ran Mun, Seoul (KR); Chan Hoon Jung, Seoul (KR); Eui Jung Jung, Seoul (KR); and Ki Woon Sung, Seoul (KR)
Assigned to AUTOTAC INC., Seoul (KR)
Appl. No. 17/262,157
Filed by AUTOTAC INC., Seoul (KR)
PCT Filed Jul. 24, 2019, PCT No. PCT/KR2019/009205
§ 371(c)(1), (2) Date Jan. 21, 2021,
PCT Pub. No. WO2020/022785, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/702,473, filed on Jul. 24, 2018.
Prior Publication US 2021/0299253 A1, Sep. 30, 2021
Int. Cl. A61K 39/395 (2006.01); A23L 33/10 (2016.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/138 (2006.01); A61K 31/166 (2006.01); A61K 31/192 (2006.01); A61K 31/277 (2006.01); A61K 31/336 (2006.01); A61K 31/355 (2006.01); A61K 31/4015 (2006.01); A61K 31/4155 (2006.01); A61K 31/4184 (2006.01); A61K 31/421 (2006.01); A61K 31/428 (2006.01); A61K 31/4535 (2006.01); A61K 31/4709 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/50 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/5415 (2006.01); A61K 31/551 (2006.01); A61K 31/565 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 47/68 (2017.01); A61P 25/28 (2006.01); C07C 43/23 (2006.01); C07C 47/575 (2006.01); C07C 217/58 (2006.01); C07C 235/06 (2006.01); C07C 237/06 (2006.01); C07C 275/24 (2006.01); C07C 279/12 (2006.01); C07D 303/18 (2006.01)
CPC C07C 217/58 (2013.01) [A23L 33/10 (2016.08); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/138 (2013.01); A61K 31/166 (2013.01); A61K 31/192 (2013.01); A61K 31/277 (2013.01); A61K 31/336 (2013.01); A61K 31/355 (2013.01); A61K 31/4015 (2013.01); A61K 31/4155 (2013.01); A61K 31/4184 (2013.01); A61K 31/421 (2013.01); A61K 31/428 (2013.01); A61K 31/4535 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/50 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/5415 (2013.01); A61K 31/551 (2013.01); A61K 31/565 (2013.01); A61K 39/3955 (2013.01); A61K 47/54 (2017.08); A61K 47/55 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61P 25/28 (2018.01); C07C 43/23 (2013.01); C07C 47/575 (2013.01); C07C 235/06 (2013.01); C07C 237/06 (2013.01); C07C 275/24 (2013.01); C07C 279/12 (2013.01); C07D 303/18 (2013.01); C07B 2200/07 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A compound selected from the group consisting of the following compounds 1 to 13:
1) (2E,4E,6E,8E)-N-(2-(2-(2-(((R)-3-(3,4-bis(benzyloxy)phenoxy)-2-hydroxypropyl)amino)ethoxy)ethoxy)ethyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide;
2) (2E,4E,6E,8E)-N-(2-(2-(2-((3,4-bis(benzyloxy) benzyl)amino)ethoxy)ethoxy)ethyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide;
3) (R)—N-(15-(3,4-bis(benzyloxy)phenoxy)-14-hydroxy-3,6,9-trioxa-12-azapentadecyl)-4-phenylbutaneamide;
4)N-(1-(3,4-bis(benzyloxy)phenyl)-5,8,11-trioxa-2-azatridecan-13-yl)-4-phenylbutanamide;
5) 3-(3-(benzo[d][1,3]dioxol-5-yl)-1H-pyrazol-5-yl)-N-(2-(2-(2-((3-((4-fluorobenzyl)oxy)) benzyl)amino)ethoxy)ethoxy)ethyl)aniline;
6) (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxirane-2-yl)-1-oxaspiro[2.5]octan-6-yl(13E,15E,17E,19E)-1-(3-(benzyloxy)phenyl)-12-oxo-5,8-dioxa-2,11-diazahenicosa-13,15,17,19-tetraene-21-oate;
7) 3-(3,5-dichlorophenyl)-5-((R)-15-(3,4-diphenethoxyphenoxy)-14-hydroxy-6,9-dioxa-3,12-diazapentadecyl)-5-methyloxazolidine-2,4-dione;
8) (R)-1-(4-(benzyloxy)-3-(3-phenylpropoxy)phenoxy)-3-((2-(2-(2-(4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a] pyrimidin-3-yl)phenoxy)ethoxy)ethoxy)ethyl)amino)propan-2-ol;
9) (R,Z)-4-((2-(2-(2-((3-(3,4-diphenethoxyphenoxy)-2-hydroxypropyl)amino) ethoxy)ethoxy)ethyl)imino)-2-phenyl-4H-chromene-5,6,7-triol;
10) (E)-5-(4-(2-(2-(2-((3,4-bis(benzyloxy)benzyl)amino)ethoxy)ethoxy)ethoxy)styryl)benzene-1,3-diol;
11) (R)-2-(4-(benzo[d]thiazol-2-yl) phenyl)-14-(3,4-bis(benzyloxy)phenoxy)-5,8-dioxa-2,11-diazatetradecane-13-ol
12) (1E,6E)-1-(4-(2-(2-(2-(((R)-3-(3-(benzyloxy)-4-phenethoxyphenoxy)-2-hydroxypropyl)amino)ethoxy)ethoxy)ethoxy)-3-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; and
13) (R)-1-(3-phenethoxyphenoxy)-3-((2-(2-(2-((6-(trifluoromethoxy))benzo[d]thiazol-2-yl)amino)ethoxy)ethoxy)ethyl)amino)propan-2-ol,
or a pharmaceutically acceptable salt, stereoisomer, solvate, or hydrate thereof.